Entrada Therapeutics Inc (TRDA) AI Stock Analysis

• Market Cap: $257.89M
• Dividend Yield: N/A
• Average Volume (3M): 208.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.75
• Revenue Growth: -66.80%
• EPS Growth: -157.68%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.04
• Shares Outstanding: 38,037,080
• 10 Day Avg. Volume: 197,993
• 30 Day Avg. Volume: 208,530
• PEG Ratio: -0.01
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 3.06
• P/FCF Ratio: -14.43
• Enterprise Value/Market Cap: -0.08
• Enterprise Value/Revenue: -0.27
• Enterprise Value/Gross Profit: -0.28
• Enterprise Value/Ebitda: 0.23
• 1Y Price Target: $18.50
• Price Target Upside: 166.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 52 Neutral
• Price Target: $7.50 ▲(7.91% Upside)

Entrada Therapeutics Inc. faces significant financial challenges, particularly in revenue generation and profitability, which heavily impacts its overall score. Technical analysis shows positive momentum, but potential overbought conditions could limit further gains. Valuation remains a concern with a negative P/E ratio, reflecting ongoing profitability issues.

Positive Factors

Proprietary Technology

Entrada's TET platform is a key competitive advantage, enabling the development of unique therapies that can effectively deliver therapeutic agents directly into cells, potentially leading to breakthrough treatments for genetic and rare disorders.

Partnerships and Collaborations

Strategic partnerships enhance Entrada's research capabilities and provide financial support through milestone payments and royalties, which are crucial for sustaining long-term growth and innovation in the biopharmaceutical sector.

Revenue Potential

Entrada's ability to secure funding from diverse sources, including government and non-profits, underscores its potential to advance drug candidates and attract further investments, bolstering its long-term revenue prospects.

Negative Factors

Revenue Decline

A significant decline in revenue indicates challenges in maintaining sales momentum, which could hinder the company's ability to invest in R&D and sustain its competitive position over the long term.

Profitability Challenges

Persistent negative margins reflect difficulties in achieving profitability, which may limit Entrada's capacity to reinvest in its business and impact its financial stability in the medium to long term.

Cash Flow Issues

Negative cash flow highlights challenges in generating sufficient cash to fund operations and growth initiatives, potentially constraining Entrada's ability to execute its strategic objectives effectively.

Entrada Therapeutics Inc Business Overview & Revenue Model

Company Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Entrada Therapeutics generates revenue through a combination of product development partnerships, grants, and potential future product sales. The company collaborates with pharmaceutical firms and research organizations to develop its therapies, often receiving milestone payments and royalties from these partnerships. Additionally, Entrada may receive funding from government and non-profit organizations aimed at supporting research in rare and genetic diseases. As the company advances its drug candidates through clinical trials, it may also attract further investments and partnerships, enhancing its revenue potential.

Entrada Therapeutics Inc Financial Statement Overview

Summary

Entrada Therapeutics Inc. faces significant financial challenges, particularly in revenue generation and profitability. Despite a strong gross profit margin, the company struggles with negative net profit and EBIT margins, moderate leverage, and cash flow issues.

Income Statement

Entrada Therapeutics Inc. has experienced significant volatility in its revenue and profitability. The TTM data shows a sharp decline in revenue by 53.85%, with negative net and EBIT margins indicating ongoing losses. Despite a strong gross profit margin, the company struggles with profitability, as evidenced by negative net profit and EBIT margins.

Balance Sheet

The balance sheet reflects moderate leverage with a debt-to-equity ratio of 0.14, indicating manageable debt levels. However, the company has a negative return on equity, suggesting inefficiencies in generating returns for shareholders. The equity ratio is stable, showing a solid equity base relative to total assets.

Cash Flow

Cash flow analysis reveals challenges in cash generation, with negative operating cash flow and free cash flow. The free cash flow growth rate is positive, but the operating cash flow to net income ratio is negative, indicating cash flow issues despite some improvement in free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	79.48M	210.78M	129.01M	0.00	0.00	0.00
Gross Profit	76.48M	210.78M	29.13M	-1.90M	-1.12M	-326.00K
EBITDA	-94.23M	47.01M	-321.00K	-95.35M	-50.01M	-26.34M
Net Income	-73.35M	65.63M	-6.68M	-87.46M	-50.07M	-26.38M
Balance Sheet
Total Assets	448.78M	526.32M	469.19M	252.06M	305.83M	43.53M
Cash, Cash Equivalents and Short-Term Investments	354.01M	420.00M	351.97M	45.16M	291.06M	39.05M
Total Debt	54.74M	59.21M	68.23M	25.94M	0.00	0.00
Total Liabilities	69.28M	97.64M	226.83M	39.50M	7.12M	85.02M
Stockholders Equity	379.50M	428.68M	242.36M	212.55M	298.72M	-41.49M
Cash Flow
Free Cash Flow	-126.56M	-44.72M	134.19M	-96.67M	-55.44M	-27.89M
Operating Cash Flow	-123.87M	-41.56M	139.80M	-93.79M	-50.86M	-25.57M
Investing Cash Flow	9.02M	-27.80M	-138.40M	-148.65M	-4.58M	-2.32M
Financing Cash Flow	2.08M	102.96M	21.04M	479.00K	307.46M	50.09M

Entrada Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Neutral. The current price of 6.95 is above the 20-day moving average (MA) of 6.47, above the 50-day MA of 5.87, and below the 200-day MA of 8.11, indicating a neutral trend. The MACD of 0.32 indicates Negative momentum. The RSI at 57.55 is Neutral, neither overbought nor oversold. The STOCH value of 56.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TRDA.

Entrada Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TRDA	―	$257.89M	―	-18.12%	―	-66.80%	-157.68%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GNFT	―	$203.87M	-4.58	-51.06%	―	-44.94%	-274.42%
CCCC	―	$242.90M	―	-52.99%	―	16.55%	16.73%
SGMT	―	$264.13M	―	-37.89%	―	-100.00%	-62.44%
VTYX	―	$414.30M	-3.46	-48.56%	―	―	39.76%
BDTX	―	$220.34M	16.34	11.85%	―	―	―

Entrada Therapeutics Inc Corporate Events

Entrada Therapeutics Reports Q2 2025 Financial Results

Entrada Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing innovative therapies using its proprietary Endosomal Escape Vehicle (EEV) platform to target intracellular pathways. In its latest earnings report for the quarter ending June 30, 2025, Entrada Therapeutics highlighted a significant decrease in collaboration revenue compared to the previous year, alongside increased research and development expenses. The company reported a net loss of $43.1 million for the quarter, a stark contrast to the net income of $55 million in the same period last year. The company’s cash, cash equivalents, and marketable securities totaled $354 million, which is expected to support operations for the next twelve months. Despite the current financial challenges, Entrada remains committed to advancing its therapeutic candidates and leveraging its EEV platform to explore new opportunities in the biopharmaceutical sector.